The FCF Healthcare & Life Sciences Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of February 2024 we identify the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding has reached EUR 5,224m
- Biotech received 58% of the total investment volume (EUR 3,040m) with oncology being the leading indication (30%)
- In February Areteia Therapeutics secures the highest transaction volume with EUR 392m, followed by Freenome with EUR 235m and BioAge with EUR 178m
- Premji Invest (United States) is the most active investor (by deal volume), followed by Novo Holdings (Denmark) and Sands Capital (United States)
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Healthcare & Life Sciences Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024”. The Monitor is a monthly published overview of venture capital trends in
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2024”. The Monitor is a monthly published overview of venture capital trends in
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 01/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 01/2024”. The Monitor is a monthly published overview of venture capital trends in the
FCF Biotech Venture Capital Monitor – USA 12/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 12/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 12/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2023”. The Monitor is a monthly published overview of venture capital trends in the European
